Evaluate Pharma

2025 prediction
Biotech

M&A, IPO uptick expected but don't expect 'floodgates to open'

Will this year be better? Evaluate analysts made predictions in their 2025 preview—and anyone expecting a dramatic turnaround should look away now.
Nick Paul Taylor Jan 3, 2025 8:40am
NY STOCK EXCHANGE

Big Pharma regained mojo in 2022 but biotechs remain precarious

Mar 3, 2023 10:53am